Copyright © 2012 American Medical Association. All rights reserved. From: Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression Arch Ophthalmol. 2012;130(9):1145-1152. doi:10.1001/archophthalmol.2012.1043 Figure Legend: Figure 1. RIDE and RISE clinical trial design. BCVA indicates best-corrected visual acuity; CST, central subfield thickness; and OCT, optical coherence tomography. *Participants in the sham arm were allowed to cross over to monthly treatment with 0.5 mg of ranibizumab in their third year of study participation. Date of download: 10/5/2017 Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved. From: Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression Arch Ophthalmol. 2012;130(9):1145-1152. doi:10.1001/archophthalmol.2012.1043 Figure Legend: Figure 2. Distribution of Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy (DR) severity levels over time. Reported values are the percentage of participants with the stated level of DR severity at each visit per treatment group. Percentages in each time column add up to 100%. Bubble sizes are proportional to the percentage of participants in each ETDRS DR severity level grouping in a column. The solid black dot indicates the median DR severity level in each column. Sham/0.3 mg of ranibizumab/0.5 mg of ranibizumab: baseline (BL), n = 254/245/247; month 3 (M3), n = 255/246/249; and month 6 (M6), n = 255/246/250. M12 indicates month 12; M18, month 18; M24, month 24; NPDR, nonproliferative DR; and PDR, proliferative DR. Date of download: 10/5/2017 Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved. From: Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression Arch Ophthalmol. 2012;130(9):1145-1152. doi:10.1001/archophthalmol.2012.1043 Figure Legend: Figure 3. Change from baseline in Early Treatment Diabetic Retinopathy Study diabetic retinopathy severity level at month 24 in study eyes (A) and fellow eyes (B). Vertical bars are 95% confidence intervals (unadjusted). Date of download: 10/5/2017 Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved. From: Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression Arch Ophthalmol. 2012;130(9):1145-1152. doi:10.1001/archophthalmol.2012.1043 Figure Legend: Figure 4. Baseline and month 24 fundus photographs from 3 participants randomized to ranibizumab showing substantial regression of retinopathy level (A-C). In case 3 (C), the arrow indicates an area of neovascularization at baseline and the same area showing absence of neovascularization at month 24. NPDR indicates nonproliferative diabetic retinopathy; and PDR, proliferative diabetic retinopathy. Date of download: 10/5/2017 Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved. From: Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression Arch Ophthalmol. 2012;130(9):1145-1152. doi:10.1001/archophthalmol.2012.1043 Figure Legend: Figure 5. Study eye change from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy (DR) severity level at month 24 by baseline study eye severity level (level ≤53E [A] and level ≥60 [B]). Vertical bars are 95% confidence intervals (unadjusted). Date of download: 10/5/2017 Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved. From: Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression Arch Ophthalmol. 2012;130(9):1145-1152. doi:10.1001/archophthalmol.2012.1043 Figure Legend: Figure 6. Time to first diabetic retinopathy (DR) progression from baseline in the pooled RIDE and RISE population. Cumulative probabilities were calculated using the Kaplan-Meier method. Progression was defined by (1) progression from nonproliferative diabetic retinopathy (DR severity level <60) at baseline to proliferative diabetic retinopathy (DR severity level ≥60) at a later time, (2) need for panretinal photocoagulation laser, (3) vitreous hemorrhage (adverse event [AE] or slitlamp grade 0 at baseline to >0 at a later time), (4) cases identified by ophthalmoscopy, (5) vitrectomy, (6) iris neovascularization AE event, or (7) retinal neovascularization AE. * P < .001 vs sham. Date of download: 10/5/2017 Copyright © 2012 American Medical Association. All rights reserved.